Compare Abeona Therapeutics Inc (ABEO) vs Robinhood Markets, Inc. (HOOD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Robinhood Markets, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.65 (market cap $373.32M), while Robinhood Markets, Inc. trades at $110.36 (market cap $101.67B). The key difference: Robinhood Markets, Inc. is far larger — about 272.3× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Robinhood Markets, Inc. nearer its low. Which is the better fit depends on your goals.
| ABEO | HOOD | |
|---|---|---|
Market Cap | $373.32M | $101.67B |
Sector | Health | Technology |
52-Week High | $7.23 | $152.46 |
52-Week Low | $4.17 | $65.16 |
Enterprise Value | $228.22M | $102.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Robinhood (HOOD) trades at $112.90, up 0.15% with strong technical momentum as it approaches resistance near $116. The stock shows robust fundamentals with 2025 revenue reaching $4.47 billion and net income of $1.88 billion, though valuation metrics remain elevated with a P/E of 57.06. Recent positive sentiment stems from international expansion and new product launches, including AI-powered trading tools and the Trump Accounts program announced July 2026.
Outlook remains positive with 73% analyst buy ratings and $108.13 consensus target, though the stock trades above target. Key opportunities include continued revenue growth and banking expansion, while risks involve high valuation multiples and cryptocurrency revenue volatility. Q2 2026 earnings on July 29 will be crucial for validating current momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →
